GMP manufacturing services for cell and gene therapy

OXB offers end-to-end GMP manufacturing services for both lentiviral and AAV vectors. Our capabilities include process transfer, scale-up, large-scale bioreactor production (200L–2,000L), fill-finish, and commercial supply. All processes are performed under rigorous quality systems to ensure reproducible, high-yield, and regulatory-ready production.

Our global GMP facilities in the UK, US, and France provide flexible capacity to support clinical trials and commercial production. We ensure seamless scale-up, consistent quality, and reliable supply across all stages of your gene therapy program.

Yes. OXB’s integrated GMP processes are optimized for multiple vector types, delivering high-titer, reproducible, and compliant viral vector production for both lentivirus and AAV applications.

All GMP manufacturing processes at OXB are conducted under robust quality systems and validated procedures. Our experienced teams adhere to FDA, EMA, MHRA, and other global regulatory standards, ensuring reliable, regulatory-ready viral vector production.

OXB combines flexible bioreactor systems, integrated fill-finish suites, and standardized platform processes to scale production from clinical batches to full commercial supply while maintaining potency, quality, and reproducibility.

Our experienced scientists provide process transfer, development, and optimization services, leveraging proprietary platforms, automation, and analytical controls to ensure smooth scale-up and high-yield GMP manufacturing.

OXB’s combination of global GMP facilities, skilled personnel, scalable processes, and rigorous end-to-end quality controls enables reliable, efficient, and regulatory-compliant production of viral vectors from clinical trials through commercial launch.